Author

S. J. Priceman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:mouse· 5 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 2

Frequent Co-Authors

S. J. Forman· 4 shared C. Martinez· 3 shared A. K. Park· 2 shared D. Tilakawardane· 2 shared J. Ishihara· 2 shared J. K. Lee· 2 shared J. P. Murad· 2 shared T. B. Dorff· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. J. Forman

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

E. Lee, C. Cullen, J. P. Murad, D. Gumber, A. Park, J. Yang, L. Stern, L. Adkins, G. Dhapola, B. Gittins, W.-C. Chang, C. Martinez, Y. Woo, M. Cristea, L. Rodriguez, , S. J. Priceman

This study develops TAG72-CAR T cells with antigen-dependent IL-12 signaling to enhance anti-tumor activity and systemic disease targeting in ovarian cancer.

bioRxiv · Jan 6, 2023 · PreprintCancer Biology

Dexamethasone Enhances CAR T Cell Persistence and Function by Upregulating Interleukin 7 Receptor

A. Munoz, R. Urak, E. Taus, H.-J. Hsieh, K. Jin, S.-H. Lin, D. Awuah, V. Vyas, S. J. Priceman, M. Clark, S. Forman, X. Wang

This study shows dexamethasone enhances CAR T cell persistence and function by upregulating IL7R, improving anti-tumor efficacy in vivo.

bioRxiv · Aug 29, 2022 · PreprintImmunology

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy

V. Bhatia, N. V. Kamat, T. E. Pariva, L.-T. Wu, A. Tsao, K. Sasaki, L. T. Wiest, A. Zhang, D. Rudoy, R. Gulati, R. A. Patel, M. P. Roudier, L. D. True, M. C. Haffner, P. S. Nelson, , J. K. Lee

This study develops STEAP1 CAR T cell therapy for advanced prostate cancer, showing potent antitumor activity and safety in preclinical models, but also identifies antigen loss as a resistance mechanism.

bioRxiv · May 16, 2022 · PreprintCancer Biology

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophages

Y. Yamaguchi, J. Gibson, K. Ou, R. H. Ng, V. D. Jonsson, J. C. Zarif, P. P. Lee, X. Wang, C. Martinez, T. B. Dorff, S. J. Forman, S. J. Priceman

This study shows that PD-L1 blockade enhances CAR T cell activity by altering macrophage phenotypes through IFNγ signaling in the tumor microenvironment.

bioRxiv · Jan 25, 2022 · PreprintImmunology

Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity

J. P. Murad, D. Tilakawardane, A. K. Park, K. T. Kennewick, L. S. Lopez, H. J. Lee, B. J. Gittins, W.-C. Chang, C. P. Tran, C. Martinez, A. M. Wu, R. E. Reiter, T. B. Dorff, S. J. Forman, S. J. Priceman

This study shows that cyclophosphamide pre-conditioning improves CAR T cell efficacy against solid tumors by modifying the immunosuppressive tumor microenvironment without harming normal tissues.

bioRxiv · Nov 18, 2020Immunology

Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

A. K. Park, Y. Fong, N. Chen, B. Jeang, D. Tilakawardane, J. Murad, S. I. Kim, J. Lu, S. Thomas, S. J. Forman, S. J. Priceman

This study combines oncolytic viruses with CAR T cells to deliver CD19 antigen to solid tumors, enhancing CAR T cell anti-tumor responses.

bioRxiv · Nov 16, 2019Cancer Biology